More importantly, DILA1 was upregulated in tamoxifen-resistant cells and the breast cancer patients who relapsed after tamoxifen treatment, suggesting that DILA1 is a good biomarker to predict poor prognosis and tamoxifen resistance in ER-positive breast cancer patients. Here, MIR99AHG is linked to breast cancer.